Terns Pharmaceuticals (TERN) to Release Quarterly Earnings on Monday

Terns Pharmaceuticals (NASDAQ:TERN) is expected to release its Q2 2025 earnings data before the market opens on Monday, August 4th. Analysts expect Terns Pharmaceuticals to post earnings of ($0.29) per share for the quarter.

Terns Pharmaceuticals (NASDAQ:TERN) last posted its earnings results on Thursday, May 8th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.03. On average, analysts expect Terns Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Terns Pharmaceuticals Stock Performance

TERN opened at $6.05 on Monday. The business’s fifty day moving average is $4.14 and its two-hundred day moving average is $3.70. The company has a market cap of $528.41 million, a price-to-earnings ratio of -5.55 and a beta of -0.11. Terns Pharmaceuticals has a one year low of $1.87 and a one year high of $11.40.

Insider Activity at Terns Pharmaceuticals

In other Terns Pharmaceuticals news, CFO Andrew Gengos purchased 10,000 shares of the stock in a transaction dated Friday, June 27th. The shares were acquired at an average cost of $3.93 per share, for a total transaction of $39,300.00. Following the completion of the transaction, the chief financial officer directly owned 25,000 shares of the company’s stock, valued at $98,250. This trade represents a 66.67% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Amy L. Burroughs purchased 23,314 shares of the stock in a transaction dated Wednesday, June 25th. The stock was acquired at an average price of $3.87 per share, for a total transaction of $90,225.18. Following the completion of the transaction, the chief executive officer directly owned 47,083 shares of the company’s stock, valued at approximately $182,211.21. The trade was a 98.09% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought 48,314 shares of company stock worth $186,575 over the last quarter. Company insiders own 1.50% of the company’s stock.

Institutional Trading of Terns Pharmaceuticals

A number of hedge funds have recently bought and sold shares of TERN. Cubist Systematic Strategies LLC boosted its position in Terns Pharmaceuticals by 136.8% during the first quarter. Cubist Systematic Strategies LLC now owns 28,327 shares of the company’s stock worth $78,000 after acquiring an additional 16,363 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in Terns Pharmaceuticals during the first quarter worth approximately $51,000. Finally, Goldman Sachs Group Inc. boosted its position in Terns Pharmaceuticals by 21.0% during the first quarter. Goldman Sachs Group Inc. now owns 415,021 shares of the company’s stock worth $1,145,000 after acquiring an additional 71,971 shares during the last quarter. Institutional investors and hedge funds own 98.26% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on TERN shares. BMO Capital Markets lowered their price target on shares of Terns Pharmaceuticals from $26.00 to $15.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 13th. JMP Securities reiterated a “market outperform” rating and issued a $20.00 price target on shares of Terns Pharmaceuticals in a research report on Monday, April 21st. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $15.63.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.